



## **Apiject Applauds Administration's Initiative to Reshore Critical Pharmaceutical Manufacturing in the U.S.**

Apiject Systems, Corp. applauds President Trump's decisive actions under the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) initiative to reshore and secure America's pharmaceutical supply chain. We strongly support national efforts to reshore the full spectrum of drug manufacturing: from domestic active pharmaceutical ingredient (API) production to large volume drug formulation to the efficient fill-finish of bulk liquid medicines into patient-ready doses.

For many years, the United States has relied on foreign suppliers – primarily in China and India – for essential medicines used by hospitals and patients every day. This reliance increases the potential for supply chain disruptions, price volatility, and delays during global emergencies.

The President's Executive Order to prioritize domestic procurement, stockpile critical APIs, and remove regulatory barriers represents a significant step toward building a more resilient pharmaceutical manufacturing base in the United States. Strengthening domestic capacity through all stages of drug manufacturing will support national security, protect public health, and help ensure that critical medicines remain available to the American people.

— August 14, 2025